The embattled genetics company reported $44.1 million in revenue for the fiscal second quarter, down from $50 million in the same period last year. 23andMe's net loss narrowed to $59.1 million, or $2.32 per share, from $75.27 million, or $3.17 per share, a year ago.

23andMe said Monday that it's eliminating more than 200 jobs, discontinuing all its therapeutics programs and winding down its ongoing clinical trials "as quickly as practical." It's evaluating strategic options such as asset sales and licensing agreements to "maximize the value" of the therapeutic programs, the release said.